Traduction de «autolog time » (Anglais → Français) :

autologous bone marrow transplantation | autologous BMT | ABMT | autologous marrow transplantation | autologous bone marrow transplant | autologous marrow transplant

autologous blood donation | autologous blood transfusion | autologous transfusion | ABD [Abbr.]

preoperative autologous blood donation | PABD | predeposit of blood | preoperative donation | autologous donation | autologous predonation | autologous blood deposit

autologous tissue breast reconstruction [ autologous tissue-based breast reconstruction | autologous flap breast reconstruction ]

autologous bone marrow transplant [ autologous bone marrow transplantation | autologous BMT ]

autograft | autologous graft | autologous transplant | autoplastic transplant | autoplasty

autologous blood donation [ autologous donation ]

Definition: This block contains a wide variety of disorders that differ in severity and clinical form but that are all attributable to the use of one or more psychoactive substances, which may or may not have been medically prescribed. The third character of the code identifies the substance involved, and the fourth character specifies the clinical state. The codes should be used, as required, for each substance specified, but it should be noted that not all fourth character codes are applicable to all substances. Identification of the psychoactive substance should be based on as many sources of information as possible. These include sel ...[+++]f-report data, analysis of blood and other body fluids, characteristic physical and psychological symptoms, clinical signs and behaviour, and other evidence such as a drug being in the patient's possession or reports from informed third parties. Many drug users take more than one type of psychoactive substance. The main diagnosis should be classified, whenever possible, according to the substance or class of substances that has caused or contributed most to the presenting clinical syndrome. Other diagnoses should be coded when other psychoactive substances have been taken in intoxicating amounts (common fourth character .0) or to the extent of causing harm (common fourth character .1), dependence (common fourth character .2) or other disorders (common fourth character .3-.9). Only in cases in which patterns of psychoactive substance-taking are chaotic and indiscriminate, or in which the contributions of different psychoactive substances are inextricably mixed, should the diagnosis of disorders resulting from multiple drug use (F19.-) be used. | Modifiers The following fourth-character subdivisions are for use with categories F10-F19: Code Title .0 Acute intoxication A condition that follows the administration of a psychoactive substance resulting in disturbances in level of consciousness, cognition, perception, affect or behaviour, o ...

autologous transfusion | autotransfusion

54 (1) An establishment that collects autologous blood must test a sample of the blood at the time of each donation to identify both of the following:

Risk factors that may be considered include: the origin of the cells (autologous, allogeneic, xenogeneic), the ability to proliferate and/or differentiate and to initiate an immune response, the level of cell manipulation, the combination of cells with bioactive molecules or structural materials, the nature of the gene therapy medicinal products, the extent of replication competence of viruses or micro-organisms used in vivo, the level of integration of nucleic acids sequences or genes into the genome, the long time functionality, the ...[+++]risk of oncogenicity and the mode of administration or use.

Specifically it means we must consider the population base, skills and support services that are required to acquire and maintain advanced technologies and services such as CT scans, cardiac stress testing, MRI scanners, hip replacement surgery, organ donation programs, full time internists, TB laboratory services, renal dialysis, autologous blood banking, et cetera.

Risk factors that may be considered include: the origin of the cells (autologous, allogeneic, xenogeneic), the ability to proliferate and/or differentiate and to initiate an immune response, the level of cell manipulation, the combination of cells with bioactive molecules or structural materials, the nature of the gene therapy medicinal products, the extent of replication competence of viruses or micro-organisms used in vivo, the level of integration of nucleic acids sequences or genes into the genome, the long time functionality, the ...[+++]risk of oncogenicity and the mode of administration or use.